Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties
Authors:
Open Access
- 27 November 2013
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 143 (1) , 19-31
Abstract
The cyclooxygenase pathway is strongly implicated in breast cancer progression but the role of this pathway in the biology of breast cancer stem/progenitor cells has not been defined. Recent attention has focused on targeting the cyclooxygenase 2 (COX-2) pathway downstream of the COX-2 enzyme by blocking the activities of individual prostaglandin E (EP) receptors. Prostaglandin E receptor 4 (EP4) is widely expressed in primary invasive ductal carcinomas of the breast and antagonizing this receptor with small molecule inhibitors or shRNA directed to EP4 inhibits metastatic potential in both syngeneic and xenograft models. Breast cancer stem/progenitor cells are defined as a subpopulation of cells that drive tumor growth, metastasis, treatment resistance, and relapse. Mammosphere-forming breast cancer cells of human (MDA-MB-231, SKBR3) or murine (66.1, 410.4) origin of basal-type, Her-2 phenotype and/or with heightened metastatic capacity upregulate expression of both EP4 and COX-2 and are more tumorigenic compared to the bulk population. In contrast, luminal-type or non-metastatic counterparts (MCF7, 410, 67) do not increase COX-2 and EP4 expression in mammosphere culture. Treatment of mammosphere-forming cells with EP4 inhibitors (RQ-15986, AH23848, Frondoside A) or EP4 gene silencing, but not with a COX inhibitor (Indomethacin) reduces both mammosphere-forming capacity and the expression of phenotypic markers (CD44hi/CD24low, aldehyde dehydrogenase) of breast cancer stem cells. Finally, an orally delivered EP4 antagonist (RQ-08) reduces the tumor-initiating capacity and markedly inhibits both the size of tumors arising from transplantation of mammosphere-forming cells and phenotypic markers of stem cells in vivo. These studies support the continued investigation of EP4 as a potential therapeutic target and provide new insight regarding the role of EP4 in supporting a breast cancer stem cell/tumor-initiating phenotype.Keywords
This publication has 35 references indexed in Scilit:
- A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasisOncoImmunology, 2013
- Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxiaProceedings of the National Academy of Sciences, 2012
- Functional Heterogeneity of Breast Fibroblasts Is Defined by a Prostaglandin Secretory Phenotype that Promotes Expansion of Cancer-Stem Like CellsPLOS ONE, 2011
- Prostaglandin E2 Regulates Renal Cell Carcinoma Invasion through the EP4 Receptor-Rap GTPase Signal Transduction PathwayJournal of Biological Chemistry, 2011
- Role of COX-2 in Tumorospheres Derived from a Breast Cancer Cell LineJournal of Surgical Research, 2011
- Prostaglandin E Receptor EP1 Suppresses Breast Cancer Metastasis and Is Linked to Survival Differences and Cancer DisparitiesMolecular Cancer Research, 2010
- Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ DiagnosisJNCI: Journal of the National Cancer Institute, 2010
- Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signalingJournal of Experimental Medicine, 2009
- Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK functionBreast Cancer Research and Treatment, 2008
- Increased EP4 Receptor Expression in Colorectal Cancer Progression Promotes Cell Growth and Anchorage IndependenceCancer Research, 2006